Pulse Explore Journal Club Debates Trending Researchers Journals

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy | Synapse

February 17, 2021New England Journal of Medicine334 citationsOpen Access

View Full Paper

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

ECElise A. Chong MRMarco Ruella SSStephen J. Schuster

Key Points

Key points are not available for this paper at this time.

Abstract

Long-Term Follow-up of CAR T-Cell–Treated Lymphoma Progression-free survival at 5 years was 31% in patients with diffuse large B-cell lymphoma and 43% in patients with follicular lymphoma. A total ...

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Chong et al. (Wed,) studied this question.

synapsesocial.com/papers/6a5d3f533ce08021578a3d01 https://doi.org/https://doi.org/10.1056/nejmc2030164

Ask AI

Helpful

Bookmark

Share

View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas2017 · 1,874 citations
2Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017 · 6,035 citations
3KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma2020 · 1,855 citations
4Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial2018 · 2,290 citations
5Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma2018 · 4,116 citations